KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.82 USD
+0.11 (1.64%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $6.87 +0.05 (0.73%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
Brokerage Reports
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 41 - 60 ( 366 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: Wedbush Securities Inc.
Analyst: AROUNIAN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS- & EYSUVIS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY21: Looking to Expanded Coverage to Accelerate Sales,Pipeline Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
2021 Financial Results Reported; Reiterate Buy; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS? & EYSUVIS?
Provider: WEDBUSH SECURITIES INC.
Analyst: AROUNIAN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS- &EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
EYSUVIS Commercial Coverage Expanded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: AROUNIAN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS? & EYSUVIS?
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A